Efficacy of a canarypox virus-vectored vaccine against feline leukaemia

Canarypox virus recombinant vaccines have a unique efficacy and safety profile for the vaccinated host because the canarypox virus is non-replicative in mammalian hosts. After the vaccination of a mammalian species, recombinant canarypox viruses express the inserted genes but cannot multiply in the...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary record 2003-08, Vol.153 (5), p.141-145
Main Authors: Poulet, H., Brunet, S., Boularand, C., Guiot, A. L., Leroy, V., Tartaglia, J., Minke, J., Audonnet, J. C., Desmettre, P.
Format: Article
Language:English
Subjects:
Animals
Antibody Formation
Canarypox virus
Canarypox virus - genetics
Cats
Chick Embryo
Gene Expression Regulation
genes
hosts
immune response
leukemia
Leukemia Virus, Feline - immunology
Leukemia, Feline - immunology
Leukemia, Feline - prevention & control
recombinant vaccines
vaccination
Vaccines, Synthetic - immunology
Vaccines, Synthetic - pharmacology
viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canarypox virus recombinant vaccines have a unique efficacy and safety profile for the vaccinated host because the canarypox virus is non-replicative in mammalian hosts. After the vaccination of a mammalian species, recombinant canarypox viruses express the inserted genes but cannot multiply in the host. They stimulate a strong immune response in the absence of any virus amplification in the host or any viral spread into the environment. A new canarypox-based recombinant vaccine is the canarypox-feline leukaemia virus (FeLV) vaccine (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes. This paper describes experiments which demonstrate that it is effective against any oronasal FeLv challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe ‘in-contact’ challenge. Furthermore, the canarypox virus-FeLv vaccine was effective without an adjuvant.
ISSN:0042-4900
2042-7670
DOI:10.1136/vr.153.5.141